Reviewing Proteon Therapeutics Inc. (PRTO)’s and Alpine Immune Sciences Inc. (NASDAQ:ALPN)’s results

Both Proteon Therapeutics Inc. (NASDAQ:PRTO) and Alpine Immune Sciences Inc. (NASDAQ:ALPN) are Biotechnology companies, competing one another. We will compare their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Proteon Therapeutics Inc. N/A 0.00 21.02M -1.19 0.00
Alpine Immune Sciences Inc. N/A 126.12 29.67M -1.98 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics Inc. 0.00% -293.7% -61%
Alpine Immune Sciences Inc. 0.00% -43.3% -39.1%

Risk and Volatility

A beta of 1.54 shows that Proteon Therapeutics Inc. is 54.00% more volatile than Standard and Poor’s 500. Alpine Immune Sciences Inc.’s 11.00% less volatile than Standard and Poor’s 500 which is a result of the 0.89 beta.


The Current Ratio of Proteon Therapeutics Inc. is 10.7 while its Quick Ratio stands at 10.7. The Current Ratio of rival Alpine Immune Sciences Inc. is 9.2 and its Quick Ratio is has 9.2. Proteon Therapeutics Inc. is better equipped to clear short and long-term obligations than Alpine Immune Sciences Inc.

Analyst Ratings

The Recommendations and Ratings for Proteon Therapeutics Inc. and Alpine Immune Sciences Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Proteon Therapeutics Inc. 0 0 1 3.00
Alpine Immune Sciences Inc. 0 0 0 0.00

Insider and Institutional Ownership

Roughly 70.3% of Proteon Therapeutics Inc. shares are held by institutional investors while 54.8% of Alpine Immune Sciences Inc. are owned by institutional investors. Proteon Therapeutics Inc.’s share held by insiders are 1%. Competitively, insiders own roughly 28.26% of Alpine Immune Sciences Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Proteon Therapeutics Inc. 6.02% 6.33% -21.78% -30.98% -4.86% -7.37%
Alpine Immune Sciences Inc. 0% -0.47% -27.16% -47.88% -53.22% -57.14%

For the past year Proteon Therapeutics Inc. has stronger performance than Alpine Immune Sciences Inc.


On 5 of the 8 factors Proteon Therapeutics Inc. beats Alpine Immune Sciences Inc.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.